£5k to spend? 3 FTSE 100 shares I’d buy in an ISA today

There are scores of FTSE 100 shares looking mighty cheap today, says Royston Wild. Why not take a look at these blue-chip bruisers?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The fresh sell-off at the start of May has left plenty of British blue chips looking too cheap to miss. I’d certainly buy GlaxoSmithKline (LSE: GSK) today. It’s failed to track its FTSE 100 rival AstraZeneca higher in recent weeks. And this leaves it dealing on an undemanding forward price-to-earnings ratio of 14 times and carrying a chunky 5% dividend yield, too.

The earnings outlook at Glaxo is always at risk of high-profile failures at the lab bench. Setbacks here can cost many millions in lost revenues and extra costs. But this particular pharma giant has a terrific R&D record. You don’t become one of the world’s largest drugs producers by accident. Just this week its Zejula treatment for patients with ovarian cancer received the approval of Food and Drug Administration officials in the US to keep its proud record going.

Recent successes are also why group sales rocketed 19% in the first quarter of 2020, to £9.1bn. It’s likely that revenues will keep booming as its packed product pipeline delivers the goods, too. In the near term, demand for its medicines won’t be hit by the coronavirus outbreak, such is the essential nature of these products. And over the long term Glaxo can expect a combination of growing global populations and rising healthcare investment in emerging markets to drive sales of its treatments.

Another FTSE 100 star

RSA Insurance Group is another Footsie share worthy of consideration today. A prospective earnings multiple of 8 times sits well below the bargain benchmark of 10 times and below. It’s a reading which fails to reflect the resilience of insurance goliaths like this in times of severe macroeconomic upheaval.

This particular blue chip’s diversified product lines, encompassing the likes of home, motor, travel and pet cover, provides it with additional safety. Investors can also take heart from RSA’s drive to improve underwriting to support earnings in these hard times. Such measures helped the FTSE 100 firm to print record underwriting profits in 2019.

Screen of price moves in the FTSE 100

A sweet selection

I’d also stock up on shares in Coca-Cola HBC for May. The drinks giant isn’t likely to be as resilient as FTSE 100 compatriots Glaxo or RSA as lockdown measures persist. Indeed, demand from the ‘out-of-home’ segment is set to be hit hard as citizens all over Europe are forced to stay indoors.

I reckon that Coca-Cola HBC will fare resolutely as quarantine measures are steadily unwound, though. Fast-moving consumer goods (or FMCGs) with titanic brand power like this usually fare better than the broader market in tough economic times. I don’t expect demand for the world’s best-loved soft drink to sink during the upcoming coronavirus-linked global recession, then.

And Coca-Cola HBC certainly looks cheap compared with some other FTSE 100-quoted FMCG stars. It trades on an earnings multiple of around 17 times for 2020. By comparison, Reckitt Benckiser Group and Diageo for example trade on forward P/E ratios in the mid-20s. I’d happily buy this large cap for my own ISA.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild owns shares of Diageo. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Diageo. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »